---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-007929"
form_type: "8-K"
ticker: "XBIO"
cik: "0001534525"
company_name: "Xenetic Biosciences, Inc."
filed_at: "2024-11-13T23:59:59+00:00"
generated_at: "2026-05-30T00:53:56.275699+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Xenetic Q3 net loss $0.4M, R&D down 64% to $0.4M, cash $6.8M; advancing DNase platform toward Phase 1

## Summary
- Net loss of $0.4M for Q3 2024; no material revenue reported.
- R&D expenses fell 63.9% YoY to $0.4M from $1.0M due to lower process development spending.
- Cash and equivalents were $6.8M at September 30, 2024.
- Preclinical data for DNase I combination therapies in colorectal cancer models completed; presented at SITC 2024.
- Strategic focus on institutional partnerships with Tokyo Medical University and Scripps Research Institute.

## SEC filing metadata
- accession: 0001683168-24-007929
- form_type: 8-K
- ticker: XBIO
- cik: 0001534525
- company_name: Xenetic Biosciences, Inc.
- filed_at: 2024-11-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/0001683168-24-007929-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1534525/000168316824007929/xenetic_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-007929
- JSON: https://secwatch.observer/filing/0001683168-24-007929.json
- Plain text: https://secwatch.observer/filing/0001683168-24-007929.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.